The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling

Our results demonstrate that the FN1-ITGB4 axis drives chemoresistance in bladder cancer via FAK signaling. Targeting this axis represents a promising strategy to overcome chemoresistance.

Institutions

Publication Details

Journal
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Published
2025-12-11
DOI
https://doi.org/10.32604/or.2025.072084
Primary Topic
Cell Adhesion Molecules Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Cell Adhesion Molecules Research
article

The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling

article en

Abstract

Our results demonstrate that the FN1-ITGB4 axis drives chemoresistance in bladder cancer via FAK signaling. Targeting this axis represents a promising strategy to overcome chemoresistance.

Oncology Research Featuring Preclinical and Clinical Cancer TherapeuticsVol. 34(2)
The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Chongqing Medical University (CN)
Openalex Percentile: Top 31%
Cell Adhesion Molecules Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2025) | TGRS Research Map | TGRS